BIIB122

AssetAlso DNL151

Small-molecule LRRK2 kinase inhibitor

Stage: Phase 2
Modality: Small molecule
Target: Autophagy; 1
Indication: 0
Trials: 1
Developer

Indications

1

LRRK2 Parkinson's disease
Phase 2, investors.denalitherapeutics.com, 7 Oct 2026

In the full profile

Targets and what it contains2
Owner and partners1
Evidence for its targets2
Competitors2
Aging relevance2

Every asset’s record: target, stage, trials and the evidence behind it.